Do analysts prefer RDY or ADPT?

Adaptive Biotechnologies has a consensus target price of $20.33, suggesting a potential downside of 3.62%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Dr. Reddy's Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dr. Reddy's Laboratories 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Adaptive Biotechnologies 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media favor RDY or ADPT?

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 2 mentions for Dr. Reddy's Laboratories. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dr. Reddy's Laboratories 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer KRYS or ADPT?

In the previous week, Krystal Biotech had 4 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 9 mentions for Krystal Biotech and 5 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Krystal Biotech's score of 0.35 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Krystal Biotech 3 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CYTK or ADPT?

In the previous week, Cytokinetics had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Cytokinetics and 5 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Cytokinetics' score of 0.70 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytokinetics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ADPT or NUVL?

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Nuvalent. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 4 mentions for Nuvalent. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Nuvalent's score of 0.72 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Adaptive Biotechnologies (ADPT) Competitors

$21.10 +0.14 (+0.66%)

As of 10:00 AM Eastern

Compare

ADPT vs. RDY, SMMT, KRYS, CYTK, and NUVL

Should you buy Adaptive Biotechnologies stock or one of its competitors? MarketBeat compares Adaptive Biotechnologies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Adaptive Biotechnologies include Dr. Reddy's Laboratories (RDY), Summit Therapeutics (SMMT), Krystal Biotech (KRYS), Cytokinetics (CYTK), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry.

How does Adaptive Biotechnologies compare to Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories (NYSE:RDY) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

3.9% of Dr. Reddy's Laboratories shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 2.0% of Dr. Reddy's Laboratories shares are held by company insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Dr. Reddy's Laboratories has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

Dr. Reddy's Laboratories has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Dr. Reddy's Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dr. Reddy's Laboratories	$3.58B	3.47	$456M	$0.58	25.65
Adaptive Biotechnologies	$295.41M	11.43	-$59.50M	-$0.33	N/A

Dr. Reddy's Laboratories has a net margin of 12.90% compared to Adaptive Biotechnologies' net margin of -16.82%. Dr. Reddy's Laboratories' return on equity of 12.34% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dr. Reddy's Laboratories	12.90%	12.34%	8.24%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Dr. Reddy's Laboratories. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 2 mentions for Dr. Reddy's Laboratories. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Dr. Reddy's Laboratories' score of -0.23 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dr. Reddy's Laboratories	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies has a consensus target price of $20.33, suggesting a potential downside of 3.62%. Given Adaptive Biotechnologies' stronger consensus rating and higher probable upside, analysts plainly believe Adaptive Biotechnologies is more favorable than Dr. Reddy's Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dr. Reddy's Laboratories	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Adaptive Biotechnologies beats Dr. Reddy's Laboratories on 9 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Summit Therapeutics?

Adaptive Biotechnologies (NASDAQ:ADPT) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, analyst recommendations, valuation, media sentiment, institutional ownership, risk, earnings and dividends.

Adaptive Biotechnologies presently has a consensus target price of $20.33, suggesting a potential downside of 3.62%. Summit Therapeutics has a consensus target price of $27.23, suggesting a potential upside of 88.80%. Given Summit Therapeutics' higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47

Adaptive Biotechnologies has higher revenue and earnings than Summit Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$295.41M	11.43	-$59.50M	-$0.33	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A

Adaptive Biotechnologies has a beta of 2.16, suggesting that its stock price is 116% more volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.32, suggesting that its stock price is 232% less volatile than the broader market.

Summit Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Summit Therapeutics	N/A	-291.24%	-243.07%

In the previous week, Adaptive Biotechnologies had 4 more articles in the media than Summit Therapeutics. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 1 mentions for Summit Therapeutics. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Summit Therapeutics' score of 0.94 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Overall Sentiment
Adaptive Biotechnologies	Positive
Summit Therapeutics	Positive

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Adaptive Biotechnologies beats Summit Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Krystal Biotech?

Krystal Biotech (NASDAQ:KRYS) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

In the previous week, Krystal Biotech had 4 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 9 mentions for Krystal Biotech and 5 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Krystal Biotech's score of 0.35 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Krystal Biotech	3 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Krystal Biotech has a net margin of 53.92% compared to Adaptive Biotechnologies' net margin of -16.82%. Krystal Biotech's return on equity of 19.25% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Krystal Biotech	53.92%	19.25%	17.62%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

86.3% of Krystal Biotech shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 13.1% of Krystal Biotech shares are held by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Krystal Biotech has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Krystal Biotech	$417.30M	26.06	$204.83M	$7.48	49.32
Adaptive Biotechnologies	$295.41M	11.43	-$59.50M	-$0.33	N/A

Krystal Biotech has a beta of 0.53, meaning that its stock price is 47% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market.

Krystal Biotech presently has a consensus price target of $340.56, suggesting a potential downside of 7.69%. Adaptive Biotechnologies has a consensus price target of $20.33, suggesting a potential downside of 3.62%. Given Adaptive Biotechnologies' higher probable upside, analysts clearly believe Adaptive Biotechnologies is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Krystal Biotech beats Adaptive Biotechnologies on 12 of the 16 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Cytokinetics?

Cytokinetics (NASDAQ:CYTK) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.

Adaptive Biotechnologies has a net margin of -16.82% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytokinetics	-784.02%	N/A	-52.86%
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. 2.6% of Cytokinetics shares are owned by insiders. Comparatively, 5.7% of Adaptive Biotechnologies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Adaptive Biotechnologies has higher revenue and earnings than Cytokinetics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytokinetics	$88.04M	120.58	-$784.96M	-$6.84	N/A
Adaptive Biotechnologies	$295.41M	11.43	-$59.50M	-$0.33	N/A

Cytokinetics has a beta of 0.42, indicating that its stock price is 58% less volatile than the broader market. Comparatively, Adaptive Biotechnologies has a beta of 2.16, indicating that its stock price is 116% more volatile than the broader market.

Cytokinetics presently has a consensus price target of $100.00, indicating a potential upside of 17.21%. Adaptive Biotechnologies has a consensus price target of $20.33, indicating a potential downside of 3.62%. Given Cytokinetics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Cytokinetics is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytokinetics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Cytokinetics had 3 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 8 mentions for Cytokinetics and 5 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Cytokinetics' score of 0.70 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytokinetics	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adaptive Biotechnologies beats Cytokinetics on 9 of the 17 factors compared between the two stocks.

How does Adaptive Biotechnologies compare to Nuvalent?

Adaptive Biotechnologies (NASDAQ:ADPT) and Nuvalent (NASDAQ:NUVL) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

Nuvalent has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Adaptive Biotechnologies' return on equity of -40.06% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Nuvalent	N/A	-40.11%	-35.43%

Adaptive Biotechnologies presently has a consensus target price of $20.33, suggesting a potential downside of 3.62%. Nuvalent has a consensus target price of $127.73, suggesting a potential upside of 3.43%. Given Nuvalent's higher possible upside, analysts plainly believe Nuvalent is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15

Adaptive Biotechnologies has a beta of 2.16, meaning that its stock price is 116% more volatile than the broader market. Comparatively, Nuvalent has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

In the previous week, Adaptive Biotechnologies had 1 more articles in the media than Nuvalent. MarketBeat recorded 5 mentions for Adaptive Biotechnologies and 4 mentions for Nuvalent. Adaptive Biotechnologies' average media sentiment score of 1.05 beat Nuvalent's score of 0.72 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nuvalent	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adaptive Biotechnologies has higher revenue and earnings than Nuvalent. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$295.41M	11.43	-$59.50M	-$0.33	N/A
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A

99.2% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 97.3% of Nuvalent shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 5.0% of Nuvalent shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Adaptive Biotechnologies beats Nuvalent on 12 of the 15 factors compared between the two stocks.

Get Adaptive Biotechnologies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ADPT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ADPT vs. The Competition

Export

Metric	Adaptive Biotechnologies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.37B	$3.63B	$6.84B	$12.34B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-63.76	21.47	25.87	24.19
Price / Sales	11.43	340.70	553.99	100.49
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	14.35	8.38	10.79	6.42
Net Income	-$59.50M	$23.92M	$3.58B	$337.00M
7 Day Performance	21.46%	2.52%	2.49%	0.94%
1 Month Performance	39.26%	0.15%	0.21%	-0.66%
1 Year Performance	78.95%	66.07%	35.20%	27.96%

Adaptive Biotechnologies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ADPT Adaptive Biotechnologies	2.542 of 5 stars	$21.10 +0.7%	$20.33 -3.6%	+77.9%	$3.37B	$295.41M	N/A	790	Positive News Gap Down
RDY Dr. Reddy's Laboratories	1.4628 of 5 stars	$13.91 +4.7%	N/A	+2.2%	$11.09B	$3.58B	23.99	27,527	High Trading Volume
SMMT Summit Therapeutics	3.7358 of 5 stars	$14.28 +3.9%	$27.23 +90.7%	-32.0%	$10.67B	N/A	N/A	110
KRYS Krystal Biotech	2.2584 of 5 stars	$343.43 -1.3%	$340.56 -0.8%	+168.0%	$10.26B	$417.30M	45.91	210	Insider Trade Gap Down
CYTK Cytokinetics	3.0249 of 5 stars	$79.17 +0.5%	$99.30 +25.4%	+147.8%	$9.80B	$88.04M	N/A	250	Analyst Upgrade Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ADPT) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RDY, SMMT, KRYS, CYTK, and NUVL

How does Adaptive Biotechnologies compare to Dr. Reddy's Laboratories?

Summary

How does Adaptive Biotechnologies compare to Summit Therapeutics?

Summary

How does Adaptive Biotechnologies compare to Krystal Biotech?

Summary

How does Adaptive Biotechnologies compare to Cytokinetics?

Summary

How does Adaptive Biotechnologies compare to Nuvalent?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Adaptive Biotechnologies (ADPT) Competitors

ADPT vs. RDY, SMMT, KRYS, CYTK, and NUVL

How does Adaptive Biotechnologies compare to Dr. Reddy's Laboratories?

Do institutionals & insiders hold more shares of RDY or ADPT?

Which has more volatility and risk, RDY or ADPT?

Which has higher earnings & valuation, RDY or ADPT?

Is RDY or ADPT more profitable?

Does the media favor RDY or ADPT?

Do analysts prefer RDY or ADPT?

Summary

How does Adaptive Biotechnologies compare to Summit Therapeutics?

Do analysts recommend ADPT or SMMT?

Which has stronger earnings & valuation, ADPT or SMMT?

Which has more volatility and risk, ADPT or SMMT?

Is ADPT or SMMT more profitable?

Does the media refer more to ADPT or SMMT?

Do institutionals and insiders have more ownership in ADPT or SMMT?

Summary

How does Adaptive Biotechnologies compare to Krystal Biotech?

Does the media prefer KRYS or ADPT?

Is KRYS or ADPT more profitable?

Do insiders & institutionals hold more shares of KRYS or ADPT?

Which has stronger earnings & valuation, KRYS or ADPT?

Which has more risk & volatility, KRYS or ADPT?

Do analysts prefer KRYS or ADPT?

Summary

How does Adaptive Biotechnologies compare to Cytokinetics?

Is CYTK or ADPT more profitable?

Do insiders and institutionals believe in CYTK or ADPT?

Which has better valuation & earnings, CYTK or ADPT?

Which has more volatility & risk, CYTK or ADPT?

Do analysts recommend CYTK or ADPT?

Does the media prefer CYTK or ADPT?

Summary

How does Adaptive Biotechnologies compare to Nuvalent?

Is ADPT or NUVL more profitable?

Do analysts recommend ADPT or NUVL?

Which has more volatility & risk, ADPT or NUVL?

Does the media refer more to ADPT or NUVL?

Which has preferable earnings & valuation, ADPT or NUVL?

Do institutionals & insiders hold more shares of ADPT or NUVL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADPT vs. The Competition

Adaptive Biotechnologies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools